REVVITY, INC. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Revvity agreed on July 31, 2026 to divest its China Immunodiagnostics (China IDX) business, which represented approximately 6% of FY2025 total revenue (~$174M of $2.9B). The transaction is expected to close by end of 2027, subject to regulatory approvals. Pro forma consideration is estimated at $140M; pro forma loss on disposition is ~$42M after tax. The company reframed Q2 and full-year 2026 guidance on a pro forma basis excluding China IDX.
Why this rating
6% revenue divestiture is moderate in scale (~$174M ÷ $12.9B market cap = 1.3%). Strategic portfolio trimming, not transformational. Modest $42M loss. Offsetting: Q2 beats expectations, Diagnostics segment up 11% organic, guidance raised.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.